ICCM vs. NVRO, STIM, SGHT, INGN, TLSI, PROF, CVRX, ELMD, KRMD, and PDEX
Should you be buying IceCure Medical stock or one of its competitors? The main competitors of IceCure Medical include Nevro (NVRO), Neuronetics (STIM), Sight Sciences (SGHT), Inogen (INGN), TriSalus Life Sciences (TLSI), Profound Medical (PROF), CVRx (CVRX), Electromed (ELMD), KORU Medical Systems (KRMD), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry.
IceCure Medical vs. Its Competitors
IceCure Medical (NASDAQ:ICCM) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.
Nevro has a net margin of -16.54% compared to IceCure Medical's net margin of -467.37%. Nevro's return on equity of -23.52% beat IceCure Medical's return on equity.
IceCure Medical presently has a consensus price target of $2.50, indicating a potential upside of 147.52%. Nevro has a consensus price target of $5.36, indicating a potential downside of 8.29%. Given IceCure Medical's stronger consensus rating and higher possible upside, research analysts clearly believe IceCure Medical is more favorable than Nevro.
In the previous week, IceCure Medical had 3 more articles in the media than Nevro. MarketBeat recorded 3 mentions for IceCure Medical and 0 mentions for Nevro. IceCure Medical's average media sentiment score of 0.82 beat Nevro's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the media.
IceCure Medical has higher earnings, but lower revenue than Nevro. IceCure Medical is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 95.5% of Nevro shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 3.2% of Nevro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
IceCure Medical has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Summary
IceCure Medical and Nevro tied by winning 8 of the 16 factors compared between the two stocks.
Get IceCure Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IceCure Medical Competitors List
Related Companies and Tools
This page (NASDAQ:ICCM) was last updated on 7/16/2025 by MarketBeat.com Staff
Free ICCM Stock Alerts